Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BGI Buys Genome Mapping System

July 31, 2014 2:21 pm | News | Comments

BioNano Genomics announced the purchase of an Irys System by BGI, the world's largest genomics organization. BGI selected BioNano's platform to enable comprehensive exploration of human structural variation and to provide vastly improved assemblies for various organisms of interest, including those where no reference exists. Read more...

TOPICS:

Replikin Count Predicts Ebola Outbreaks

July 31, 2014 2:14 pm | News | Comments

Replikins Ltd. released new data on changes in the gene structure of the Ebola virus showing that before the current outbreaks, the mean Ebola Reston gene Replikin Count between 1995 and 2002 was 1.1; the mean Replikin Count increased two-fold in 2010, three-fold in 2012, and sixteen-fold in 2013. Read more...

TOPICS:

Transplantation Works Well in Immunodeficient Children

July 31, 2014 2:07 pm | News | Comments

Babies who are born with severe combined immunodeficiency can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard O’Reilly, MD, a world-renowned pioneer in the development of transplant protocols. Read more...

TOPICS:
Advertisement

Thyroid Cancer Drug Approved for Accelerated Assessment

July 31, 2014 1:59 pm | News | Comments

The European Medicines Agency has approved Eisai's request for accelerated assessment of the investigational oral multiple receptor tyrosine kinase inhibitor lenvatinib, for the treatment of patients with progressive radioiodine-refractory, differentiated thyroid cancer. Read more...

TOPICS:

AFFiRiS, MJFF Make Progress on Parkinson's Vaccine

July 31, 2014 1:56 pm | News | Comments

AFFiRiS announced results of a Phase 1 clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. Read more...   

TOPICS:

Kala Initiates Phase 2 Eye Drug Trials

July 31, 2014 1:43 pm | News | Comments

Kala Pharmaceuticals Inc. announced the initiation of two Phase 2 clinical trial to evaluate KP-121, the company’s loteprednol etabonate MPP (LE-MPP) drug product. Read more...                     

TOPICS:

Cannabis Science to Test Multiple Strains for Clinical Development

July 31, 2014 1:36 pm | News | Comments

Cannabis Science Inc. announced that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of clinical drugs. Read more... 

TOPICS:

Protein Fuels Repair of Treatment-Resistant Cancer Cells

July 31, 2014 1:31 pm | News | Comments

In some highly treatment-resistant cancers, such as head and neck cancer, some cancer cells repair themselves, survive and thrive during radiation and chemotherapy. Now, University of Michigan researchers have found that a particular protein— TRIP13— encourages those cancer cells to repair themselves. Read more...

TOPICS:
Advertisement

New NIH Program Will Find Potential Drug Targets

July 31, 2014 1:23 pm | News | Comments

National Institutes of Health leaders have announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. Read more...            

TOPICS:

Biorepository Management Today

July 31, 2014 1:21 pm | by Louise Rozik, Editor | Articles | Comments

Scientists are accustomed to the fickle nature of research, but sometimes it can get to even the most seasoned researcher. One especially poignant example – the Cancer Genome Atlas – starts with the completion of the Human Genome Project in 2003. Read more...

TOPICS:

Drug Target Identified for Common Childhood Blood Cancer

July 31, 2014 1:13 pm | News | Comments

In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers report that they have identified a possible new drug target for treating the disease. Read more...

TOPICS:

Gilead, Theraclone Partner on HIV Antibodies

July 31, 2014 9:46 am | News | Comments

Theraclone Sciences Inc. announced that it has entered into an agreement with Gilead Sciences Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV. Read more...

TOPICS:

Cholesterol Drug Hits Primary Endpoint in Nine Trials

July 31, 2014 9:41 am | News | Comments

Sanofi and Regeneron announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator. Read more...

TOPICS:

Naltrexone May Diminish ICD Symptoms in Parkinson's Patients

July 31, 2014 9:34 am | News | Comments

A team of investigators conducted a pilot study and found that the opioid antagonist naltrexone may be an effective treatment for diminishing symptoms of impulse control disorders (ICDs) in Parkinson's disease patients. Read more...    

TOPICS:

New Mouse Model May Open Autism Treatment Avenues

July 31, 2014 9:23 am | News | Comments

Following a hunch about a brain receptor, researchers have developed a new mouse model that may open a new avenue for testing drugs for autism. Read more...                           

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading